New York, USA, June 10, 2026 (GLOBE NEWSWIRE) -- Metastatic Prostate Cancer Market Set for Robust Growth Through 2036, Driven by The Emergence of PARP Inhibitors and PSMA-targeted Radioligand Therapies | DelveInsight
The metastatic prostate cancer market is undergoing a major transition from conventional ADT toward combination-based, biomarker-driven, and precision-targeted treatment approaches. While AR pathway inhibitors continue to dominate across mHSPC and mCRPC settings, the emergence of novel therapies such as 225Ac‑PSMA‑617 (Novartis), 177Lu-DOTA-rosopatamab (TLX591) (Telix Pharmaceuticals), Azetukalner (XEN1101) (Xenon Pharmaceuticals), Mevrometostat (PF-06821497) (Pfizer), Cabozantinib (CABOMETYX, XL184) (Exelixis, Ipsen Pharma, and Takeda), and others is significantly reshaping the treatment paradigm.
Recently published Metastatic Prostate Cancer Market Insights report includes a comprehensive understanding of current treatment practices, metastatic prostate cancer emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Metastatic Prostate Cancer Market Summary
- The market size for metastatic prostate cancer was found to be USD 11.5 billion in the 7MM in 2025.
- The United States accounted for the largest metastatic prostate cancer treatment market size in 2025, compared to other major markets, including the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
- In 2025, the total number of prevalent cases of metastatic prostate cancer in the 7MM were ~315,000.
- Key metastatic prostate cancer companies, including Novartis, Telix Pharmaceuticals, Xenon Pharmaceuticals, Pfizer, Exelixis, Ipsen Pharma, Takeda, Promontory Therapeutics, Xencor, Blue Earth Therapeutics, ORIC Pharmaceuticals, Curium, Fusion Pharmaceuticals, Merck, Orion, Kangpu Biopharmaceuticals, Lantheus, Eli Lilly and Company, and others, are actively working on innovative metastatic prostate cancer drugs.
- Some of the key metastatic prostate cancer therapies in clinical trials include 225Ac‑PSMA‑617, 177Lu-DOTA-rosopatamab (TLX591), Azetukalner (XEN1101), Mevrometostat (PF-06821497), Cabozantinib (CABOMETYX, XL184), PT-112, Vudalimab (XmAb-20717), 177Lu-rhPSMA-10.1, ORIC-944, 177Lu-PSMA-I&T, FPI-2265, Opevesostat (MK-5684; ODM-208), KPG-121, Lu-PNT2002, and others. These novel metastatic prostate cancer therapies are anticipated to enter the metastatic prostate cancer market in the forecast period and are expected to change the market.
Discover how fast will the metastatic prostate cancer market grow in the US, EU4, UK, and Japan @ https://www.delveinsight.com/report-store/metastatic-prostate-cancer-market
Key Factors Driving the Growth of the Metastatic Prostate Cancer Market
- Rising Incidence of Prostate Cancer: The growing global burden of prostate cancer, particularly among aging male populations, is increasing the number of patients progressing to metastatic disease, thereby expanding the treatment market.
- Advancements in Diagnostic Technologies: Improved imaging modalities, biomarker-based testing, and genetic profiling are enabling earlier and more accurate detection of metastatic prostate cancer, facilitating timely therapeutic intervention.
- Expansion of Novel Treatment Options: The introduction of next-generation androgen receptor inhibitors, radioligand therapies, immunotherapies, and targeted therapies has significantly broadened the treatment landscape and improved patient outcomes.
- Emerging Role of Radiopharmaceuticals: The success of prostate-specific membrane antigen (PSMA)-targeted radioligand therapies has opened a new therapeutic avenue, attracting significant investment and accelerating market growth.
- Emergence of Gene Therapies: The development of gene therapy in prostate cancer is becoming a major market driver due to its potential to deliver targeted and personalized treatment. Increasing clinical research, technological advancements, and growing investment in innovative therapies are expected to accelerate market growth and improve outcomes in advanced prostate cancer.
- Rising Clinical Trials Activities: The metastatic prostate cancer pipeline possesses promising several products in different stages of development to be approved in the near future. The emerging landscape holds a diverse range of therapeutic alternatives for treatment, including 225Ac‑PSMA‑617 (Novartis), 177Lu-DOTA-rosopatamab (TLX591) (Telix Pharmaceuticals), Azetukalner (XEN1101) (Xenon Pharmaceuticals), Mevrometostat (PF-06821497) (Pfizer), Cabozantinib (CABOMETYX, XL184) (Exelixis, Ipsen Pharma and Takeda), PT-112 (Promontory Therapeutics), Vudalimab (XmAb-20717) (Xencor), 177Lu-rhPSMA-10.1 (Blue Earth Therapeutics), ORIC-944 (ORIC Pharmaceuticals), 177Lu-PSMA-I&T (Curium), FPI-2265 (Fusion Pharmaceuticals), Opevesostat (MK-5684; ODM-208) (Merck and Orion), KPG-121 (Kangpu Biopharmaceuticals), Lu-PNT2002 (Lantheus and Eli Lilly and Company), and others. Expected launch of these therapies shall further create a positive impact on the market.
According to Aparna Thakur, project manager of forecasting at DelveInsight, the late-stage pipeline, including next-generation PARP inhibitors, AKT inhibitors, PSMA-targeted therapies, and novel AR degraders, is expected to intensify market competition and further expand precision treatment opportunities during the forecast period.
Metastatic Prostate Cancer Market Analysis
- The metastatic prostate cancer market is broadly categorized according to its response to androgen deprivation therapy (ADT), comprising metastatic castration-sensitive prostate cancer (mCSPC) and metastatic castration-resistant prostate cancer (mCRPC).
- Current treatment options for metastatic prostate cancer include ERLEADA, XTANDI, NUBEQA, JEVTANA, and ZYTIGA, with the addition of Novartis’ PLUVICTO further expanding the therapeutic landscape.
- In the mCRPC segment, alongside established therapies such as XTANDI, ZYTIGA, JEVTANA, and XOFIGO, the approval of PLUVICTO in 2022 marked a significant advancement. The radioligand therapy achieved global sales of approximately USD 1.4 billion in 2024, establishing itself as a blockbuster product.
- The mCRPC pipeline remains robust, particularly in the first-line treatment setting, where candidates such as Merck’s opevesostat and Tavanta’s TAVT-45 are being actively developed.
- In the second-line setting, CABOMETYX is expected to be among the earliest emerging therapies to secure approval, while Pfizer is targeting a 2026 launch for mevrometostat, its EZH2 inhibitor.
- For patients progressing to third-line and later therapies, several promising investigational agents are under evaluation, including 177Lu-PNT2002 (Lantheus/Eli Lilly–POINT Biopharma), AstraZeneca’s FPI-2265, ARV-766, a PROTAC androgen receptor degrader being developed by Arvinas and Novartis, and PT-112 from Promontory Therapeutics.
- A number of leading pharmaceutical companies are advancing innovative therapies for metastatic prostate cancer, including Curium, Bristol Myers Squibb, Merck and Orion, Pfizer, Merus, Zenith Epigenetics, AstraZeneca, Telix International, Novartis, Eli Lilly, POINT Biopharma, Promontory Therapeutics, Exelixis, Ipsen Pharma, Takeda, and several others.
Learn more about which drugs are losing market share @ Metastatic Prostate Cancer Treatment Market
Metastatic Prostate Cancer Competitive Landscape
Some of the metastatic prostate cancer drugs under development include 225Ac‑PSMA‑617 (Novartis), 177Lu-DOTA-rosopatamab (TLX591) (Telix Pharmaceuticals), Azetukalner (XEN1101) (Xenon Pharmaceuticals), Mevrometostat (PF-06821497) (Pfizer), Cabozantinib (CABOMETYX, XL184) (Exelixis, Ipsen Pharma and Takeda), PT-112 (Promontory Therapeutics), Vudalimab (XmAb-20717) (Xencor), 177Lu-rhPSMA-10.1 (Blue Earth Therapeutics), ORIC-944 (ORIC Pharmaceuticals), 177Lu-PSMA-I&T (Curium), FPI-2265 (Fusion Pharmaceuticals), Opevesostat (MK-5684; ODM-208) (Merck and Orion), KPG-121 (Kangpu Biopharmaceuticals), Lu-PNT2002 (Lantheus and Eli Lilly and Company), and others.
Telix's TLX591 is a leading radioligand antibody-drug conjugate (ADC) targeting prostate-specific membrane antigen (PSMA). The ProstACT clinical program, including the Phase II/III ProstACT GLOBAL study, is assessing the treatment's efficacy and safety across various stages of prostate cancer, ranging from initial recurrence to advanced metastatic disease. At present, TLX591 is undergoing evaluation in the Phase III ProstACT Global trial, with interim results from Part I expected in the near future.
Pfizer’s Mevrometostat is a highly potent and selective inhibitor of the enhancer of zeste homolog 2 (EZH2). By targeting EZH2, a key driver of prostate cancer cell proliferation, the therapy aims to suppress tumor growth. Its mechanism involves reducing levels of H3K27Me3, a protein marker associated with EZH2 activity and cancer progression.
Curium’s 177Lu-PSMA-I&T is a radiopharmaceutical therapy developed for the treatment of metastatic castration-resistant prostate cancer (mCRPC). It selectively binds to PSMA-positive tumor cells and delivers beta-radiation directly to cancerous tissue, leading to targeted cell destruction. Curium continues to support the ongoing pivotal ECLIPSE trial through uninterrupted clinical supply and patient enrollment activities.
Exelixis' lead therapeutic candidate, Cabozantinib, is a multi-targeted tyrosine kinase inhibitor that blocks several signaling pathways, including MET, AXL, VEGF receptors, and RET. The company had planned to file a supplemental New Drug Application (sNDA) with the U.S. FDA for cabozantinib in mCRPC during late 2024; however, no further updates regarding the submission or regulatory progress have been announced to date.
The anticipated launch of these emerging metastatic prostate cancer therapies are poised to transform the metastatic prostate cancer market landscape in the coming years. As these cutting-edge metastatic prostate cancer therapies continue to mature and gain regulatory approval, they are expected to reshape the metastatic prostate cancer market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
To know more about how much revenue is generated by radioligand therapies, visit @ Metastatic Prostate Cancer Medication
Recent Developments in the Metastatic Prostate Cancer Market
- In June 2026, Convergent Therapeutics Inc., has announced interim results from Part 3 of its Phase 2 CONVERGE-01 trial evaluating Ac-225 rosopatamab tetraxetan (CONV01-α) in patients with metastatic castration-resistant prostate cancer (mCRPC) who had previously received Lu-177-PSMA radioligand therapy (Lu-PSMA).
- In June 2026, Novartis reported results demonstrating consistent improvements in radiographic progression-free survival (rPFS) across key patient subgroups when Pluvicto was added to standard of care (SoC), compared with SoC alone, in patients with PSMA-positive metastatic hormone-sensitive prostate cancer (mHSPC).
- In May 2026, Johnson & Johnson reported final Phase 3 PROTEUS trial results demonstrating that the investigational regimen of ERLEADA® (apalutamide) combined with androgen deprivation therapy (ADT), administered for six months both before and after prostate cancer surgery, significantly enhanced important short- and long-term clinical outcomes compared with placebo plus ADT in patients with high-risk localized or locally advanced prostate cancer.
- In May 2026, Bayer reported that the Phase II ARACOG (AFT-47) head-to-head study achieved its primary endpoint. By week 24, men with metastatic or non-metastatic castration-resistant prostate cancer (CRPC) and metastatic castration-sensitive prostate cancer (mCSPC) treated with NUBEQA® (darolutamide) experienced significantly less cognitive decline than those receiving enzalutamide. The median maximal change in cognitive domain (MCCD) was −15.8% with NUBEQA compared with −36.1% with enzalutamide (p=0.009). The trial was conducted by the Alliance Foundation Trials.
- In March 2026, Pfizer Inc. announced encouraging topline results from the Phase 3 TALAPRO-3 study investigating TALZENNA® (talazoparib) plus XTANDI® (enzalutamide) in patients with HRR gene-mutated metastatic castration-sensitive prostate cancer (mCSPC/mHSPC).
- In February 2026, Vir Biotechnology, Inc. presented updated Phase 1 trial data for VIR-5500, a PSMA-targeting PRO-XTEN® dual-masked T-cell engager, in heavily pretreated patients with advanced mCRPC.
What is Metastatic Prostate Cancer?
Metastatic prostate cancer is an advanced stage of prostate cancer in which malignant cells spread beyond the prostate gland to other parts of the body, most commonly the bones, lymph nodes, liver, or lungs. This progression occurs when cancer cells break away from the primary tumor and travel through the bloodstream or lymphatic system, establishing new tumors in distant organs. Patients with metastatic prostate cancer may experience symptoms such as bone pain, fatigue, urinary difficulties, weight loss, and reduced quality of life. Although the disease is generally not curable at this stage, significant advances in treatment, including androgen deprivation therapy (ADT), androgen receptor pathway inhibitors, chemotherapy, radioligand therapies, and targeted treatments, have improved survival outcomes and disease management.
Metastatic Prostate Cancer Epidemiology Segmentation
The metastatic prostate cancer epidemiology section provides insights into the historical and current metastatic prostate cancer patient pool and forecasted trends for the leading markets. Based on DelveInsight's assessment in 2025, the US had ~3.8 million prevalent cases of prostate cancer. These are expected to rise due to the growing geriatric population and advancements in diagnostic capabilities during the forecast period (2026−2036).
The metastatic prostate cancer market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets segmented into:
- Total Prevalent Cases of Prostate Cancer
- Five-year Prevalent Cases of Prostate Cancer
- Total Prevalent Cases of Prostate Cancer by Clinical Stages
- Age-specific Cases of Prostate Cancer
- Total Prevalent Cases of Metastatic Prostate Cancer
Download the report to understand which companies dominate the mCRPC market @ Metastatic Prostate Cancer Treatment Options
| Metastatic Prostate Cancer Market Report Metrics | Details |
| Study Period | 2022–2036 |
| Metastatic Prostate Cancer Market Report Coverage | 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] |
| Metastatic Prostate Cancer Market Size in 2025 | USD 11.5 Billion |
| Key Metastatic Prostate Cancer Companies | Novartis, Telix Pharmaceuticals, Xenon Pharmaceuticals, Pfizer, Exelixis, Ipsen Pharma, Takeda, Promontory Therapeutics, Xencor, Blue Earth Therapeutics, ORIC Pharmaceuticals, Curium, Fusion Pharmaceuticals, Merck, Orion, Kangpu Biopharmaceuticals, Lantheus, Eli Lilly and Company, Sanofi, Bayer, Johnson & Johnson, Astellas Pharma, and others |
| Key Metastatic Prostate Cancer Therapies | 225Ac‑PSMA‑617, 177Lu-DOTA-rosopatamab (TLX591), Azetukalner (XEN1101), Mevrometostat (PF-06821497), Cabozantinib (CABOMETYX, XL184), PT-112, Vudalimab (XmAb-20717), 177Lu-rhPSMA-10.1, ORIC-944, 177Lu-PSMA-I&T, FPI-2265, Opevesostat (MK-5684; ODM-208), KPG-121, Lu-PNT2002, ZYTIGA, XTANDI, ERLEADA, JEVTANA, NUBEQA, PLUVICTO, TALZENNA, and others |
Scope of the Metastatic Prostate Cancer Market Report
- Metastatic Prostate Cancer Patient Population Forecast
- Metastatic Prostate Cancer Therapeutics Market Size
- Metastatic Prostate Cancer Pipeline Analysis
- Metastatic Prostate Cancer Market Size and Trends
- Metastatic Prostate Cancer Market Opportunity
- Metastatic Prostate Cancer Market Unmet Needs
- KOL’s Views on Metastatic Prostate Cancer
- Metastatic Prostate Cancer Market Access and Reimbursement
Discover more about late-stage prostate cancer pipeline drugs @ Metastatic Prostate Cancer Clinical Trials
Table of Contents
| 1 | Metastatic Prostate Cancer Market Key Insights |
| 2 | Metastatic Prostate Cancer Market Report Introduction |
| 3 | Executive Summary of Metastatic Prostate Cancer |
| 4 | Key Events |
| 5 | Epidemiology and Market Forecast Methodology |
| 6 | Prostate Cancer Market Overview at a Glance |
| 6.1 | Market Share (%) Distribution of Metastatic Prostate Cancer by Class in 2025 in the 7MM |
| 6.2 | Market Share (%) Distribution of Metastatic Prostate Cancer by Class in 2036 in the 7MM |
| 6.3 | Market Share (%) Distribution of Metastatic Prostate Cancer by LoT in 2025 in the 7MM |
| 6.4 | Market Share (%) Distribution of Metastatic Prostate Cancer by LoT in 2036 in the 7MM |
| 7 | Disease Background and Overview |
| 7.1 | Signs and Symptoms of Prostate Cancer |
| 7.2 | Risk Factors and Causes of Prostate Cancer |
| 7.3 | Stages of Prostate Cancer |
| 7.4 | Pathophysiology of Prostate Cancer |
| 7.5 | Diagnosis of Prostate Cancer |
| 7.6 | Treatment and Management |
| 8 | Epidemiology and Patient Population |
| 8.1 | Key Findings |
| 8.2 | Assumptions and Rationale: The 7MM |
| 8.2.1 | Total Prevalent Cases of Prostate Cancer in the 7MM |
| 8.3 | The United States |
| 8.3.1 | Five-year Prevalent Cases of Prostate Cancer in the US |
| 8.3.2 | Total Prevalent Cases of Prostate Cancer by Clinical Stages in the US |
| 8.3.3 | Age-specific Cases of Prostate Cancer in the US |
| 8.3.4 | Total Prevalent Cases of Metastatic Prostate Cancer in the US |
| 8.4 | EU4 and the UK |
| 8.5 | Japan |
| 9 | Patient Journey |
| 10 | Marketed Metastatic Prostate Cancer Drugs |
| 10.1 | Marketed Competitive Landscape of Metastatic Prostate Cancer |
| 10.2 | Cabazitaxel (JEVTANA): Sanofi |
| 10.2.1 | Product Description |
| 10.2.2 | Regulatory Milestones |
| 10.2.3 | Other Development Activities |
| 10.2.4 | Summary of Pivotal Trials |
| 10.2.5 | Analyst’s Views |
| 10.3 | Radium-223 dichloride (XOFIGO): Bayer |
| 10.4 | Abiraterone acetate (ZYTIGA): Johnson & Johnson |
| 10.5 | Enzalutamide (XTANDI): Astellas Pharma/Pfizer |
| 10.6 | Darolutamide (NUBEQA): Bayer and Orion |
| 11.7 | apalutamide (ERLEADA): Johnson & Johnson |
| 11.8 | 177Lu-PSMA-617 (PLUVICTO ): Novartis Pharmaceuticals |
| 11.9 | Talazoparib (TALZENNA): Pfizer |
| List to be continued in report… | |
| 12 | Emerging Metastatic Prostate Cancer Drugs |
| 12.1 | Competitive Landscape: Emerging Therapies |
| 12.2 | 177Lu-PSMA-I&T: Curium |
| 12.2.1 | Product Description |
| 12.2.2 | Other Developmental Activities |
| 12.2.3 | Clinical Development |
| 12.2.4 | Safety and Efficacy |
| 12.2.5 | Analyst’s Views |
| 12.3 | Opevesostat (MK-5684; ODM-208): Merck and Orion |
| 12.4 | Mevrometostat (PF-06821497): Pfizer |
| 12.5 | CABOMETYX (cabozantinib): Exelixis and Ipsen Pharma and Takeda |
| 12.6 | 177LU-PNT2002: Lantheus and Eli Lilly/Point Biopharma |
| List to be continued in the report … | |
| 13 | Metastatic Prostate Cancer Market : 7MM Analysis |
| 13.1 | Key Findings |
| 13.2 | Metastatic Prostate Cancer Market Outlook |
| 13.2.1 | CSPC |
| 13.2.2 | CRPC |
| 13.3 | Conjoint Analysis |
| 13.3.1 | CSPC |
| 13.3.2 | CRPC |
| 13.4 | Key Metastatic Prostate Cancer Market Forecast Assumptions |
| 13.5 | Total Market Size of Metastatic Prostate Cancer in the 7MM |
| 13.6 | Market Size by Metastatic Prostate Cancer by Therapies in the 7MM |
| 13.6.1 | mCSPC Market Size |
| 13.6.2 | mCRPC Market Size |
| 13.7 | Total Market Size of Metastatic Prostate Cancer by Class in the 7MM |
| 13.8 | The United States Metastatic Prostate Cancer Market |
| 13.8.1 | Total Market Size of Metastatic Prostate Cancer |
| 13.8.2 | Market Size of Metastatic Prostate Cancer by Therapies in the US |
| 13.9 | EU4 and the UK Metastatic Prostate Cancer Market |
| 13.10 | Japan Metastatic Prostate Cancer Market |
| 14 | Unmet Needs |
| 15 | SWOT Analysis |
| 16 | KOL Views |
| 17 | Metastatic Prostate Cancer Market Access and Reimbursement |
| 17.1 | United States |
| 17.2 | EU4 and the UK |
| 17.3 | Japan |
| 17.4 | Summary and Comparison of Market Access and Pricing Policy Developments in 2025 |
| 17.5 | Metastatic Prostate Cancer: Market Access and Reimbursement |
| 18 | Bibliography |
| 19 | Metastatic Prostate Cancer Market Report Methodology |
Related Reports
Metastatic Prostate Cancer Clinical Trial Analysis
Metastatic Prostate Cancer Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key metastatic prostate cancer companies, including Telix Pharmaceuticals, Candel Therapeutics, Astellas Pharma, ORIC Pharmaceuticals, Roche, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Geode Therapeutics Inc., Cullgen, AstraZeneca, TYK Medicines, Inc., K36 Therapeutics, Inc., Bristol-Myers Squibb, Kyntra Bio, ARTBIO Inc., Acerand Therapeutics, Janux Therapeutics, Evopoint Biosciences Inc., AbbVie, Arsenal Biosciences, Inc., Fusion Pharmaceuticals Inc., and others.
Radioligand Therapies Market Size, Target Population, Competitive Landscape & Market Forecast – 2034 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key RLT companies, including Novartis, Curium Pharma, Lantheus, Eli Lilly and Company, Fusion Pharmaceuticals, AstraZeneca, Clarity Pharmaceuticals, Bayer, ITM Isotope Technologies, ARTBIO, Convergent Therapeutics, Perspective Therapeutics, PRECIRIX, Ariceum Therapeutic, Nuclidium, and others.
PSMA-targeted Therapy Market Size, Target Population, Competitive Landscape & Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key PSMA-targeted therapy companies, including Lantheus, Telix Pharmaceuticals, Novartis, and others.
Metastatic Castration-Resistant Prostate Cancer Market
Metastatic Castration-Resistant Prostate Cancer Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key metastatic castration-resistant prostate cancer companies including AstraZeneca, Arvinas, Madison Vaccines, Phosplatin Therapeutics, Hinova Pharmaceuticals, Bristol Myers Squibb, Merck, MacroGenics, Daiichi Sankyo, Seagen, Taiho Pharmaceutical, Modra Pharmaceuticals, Xencor, Point Biopharma, Lantheus Holdings, Zenith Epigenetics, Essa Pharma, Telix Pharmaceuticals, Kintor Pharmaceutical, AB Science, Eli Lilly and Company, Exelixis, and others.
Metastatic Castration-Sensitive Prostate Cancer Market
Metastatic Castration-Sensitive Prostate Cancer Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key mCSPC companies including Myovant Sciences, Pfizer, Bayer, Orion, Novartis, AstraZeneca, Pfizer, Janssen, Merck, Eli Lilly, and others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us Shruti Thakur info@delveinsight.com +14699457679
